Eiger BioPharmaceuticals

Eiger is a biopharmaceutical company developing new antiviral agents against novel targets in the treatment of hepatitis.

Eiger BioPharmaceuticals is a privately held biotechnology company developing a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Eiger’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.